The Candidemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Candidemia pipeline products will significantly revolutionize the Candidemia market dynamics.
DelveInsight’s “Candidemia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Candidemia, historical and forecasted epidemiology as well as the Candidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Candidemia market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Candidemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Candidemia Market Insights
Some of the key facts of the Candidemia Market Report:
- The Candidemia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Rezafungin was approved by the Antimicrobial Drugs Advisory Committee of the US Food and Drug Administration (FDA) to treat candidemia and invasive candidiasis in adult patients by a vote of 14 to 1. This was announced by Cidara Therapeutics and Melinta Therapeutics. The FDA’s advisory group found that the new drug application for rezafungin had enough data to warrant a favorable risk-benefit analysis of the treatment
- The total diagnosed incident population of Candidemia in the 7MM countries was estimated to be more than 40,000 cases in 2020, with the United States, contributing approximately 23,337 cases in 2020, 55% of incident candidemia patients were males whereas 45% were females, in Japan
- Among the European countries, Spain had the highest population of candidemia with approximately 6,214 cases, followed by Germany, which had approximately 3,457 cases in 2020
- Key Candidemia Companies: Cidara Therapeutics/Mundipharma, Pfizer (acquired Amplyx Pharmaceuticals), and others
- Key Candidemia Therapies: Rezafungin, Fosmanogepix, and others
- The Candidemia epidemiology based on gender analyzed that Candidemia is slightly more prominent in males in comparison to females
Candidemia Overview
Candidemia is a serious, life-threatening bloodstream infection and possibly the fourth most common all-type bloodstream infections seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population suffering from this disease.
Get a Free sample for the Candidemia Market Report –
https://www.delveinsight.com/sample-request/candidemia-market
Candidemia Market
The dynamics of the Candidemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.
“Basilea has focused on anti-infectives, specifically antifungals and antibiotics. The company has successfully brought two anti-infective drugs to the market: the antifungal CRESEMBA (isavuconazole) and the antibiotic ZEVTERA (ceftobiprole). ISAVUCONAZOLE (BAL8557) drug’s evaluation in the Phase III trial was completed for the treatment of candidemia in 2015, after which there is no update of the drug for Candidemia treatment.”
Candidemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Candidemia Epidemiology Segmentation:
The Candidemia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Candidemia
- Prevalent Cases of Candidemia by severity
- Gender-specific Prevalence of Candidemia
- Diagnosed Cases of Episodic and Chronic Candidemia
Download the report to understand which factors are driving Candidemia epidemiology trends @ Candidemia Epidemiological Insights
Candidemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Candidemia market or expected to get launched during the study period. The analysis covers Candidemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Candidemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Candidemia Therapies and Key Companies
- Rezafungin: Cidara Therapeutics/Mundipharma
- Fosmanogepix: Pfizer (acquired AmplyxPharmaceuticals)
Discover more about therapies set to grab major Candidemia market share @ Candidemia market forecast
Candidemia Market Drivers
- Upcoming launch of novel, new class anti-fungal drugs
- Increasing awareness for treating Candidemia
- Personalized treatments
Candidemia Market Barriers
- Minimizing the use of antimicrobial
- Lack of adequate diagnosis
- Lack of country-specific guidelines
Scope of the Candidemia Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Candidemia Companies: Cidara Therapeutics/Mundipharma, Pfizer (acquired Amplyx Pharmaceuticals), and others
- Key Candidemia Therapies: Rezafungin, Fosmanogepix, and others
- Candidemia Therapeutic Assessment: Candidemia current marketed and Candidemia emerging therapies
- Candidemia Market Dynamics: Candidemia market drivers and Candidemia market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Candidemia Unmet Needs, KOL’s views, Analyst’s views, Candidemia Market Access and Reimbursement
Table of Contents
1. Candidemia Market Report Introduction
2. Executive Summary for Candidemia
3. SWOT analysis of Candidemia
4. Candidemia Patient Share (%) Overview at a Glance
5. Candidemia Market Overview at a Glance
6. Candidemia Disease Background and Overview
7. Candidemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Candidemia
9. Candidemia Current Treatment and Medical Practices
10. Candidemia Unmet Needs
11. Candidemia Emerging Therapies
12. Candidemia Market Outlook
13. Country-Wise Candidemia Market Analysis (2019–2032)
14. Candidemia Market Access and Reimbursement of Therapies
15. Candidemia Market Drivers
16. Candidemia Market Barriers
17. Candidemia Appendix
18. Candidemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
To know more about Candidemia treatment, visit @ Candidemia Medications
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/